Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy for knee osteoarthritis involves the intra-articular injection of hyaluronic acid (specifically the brand Osteonil) and the corticosteroid triamcinolone hexacetonide. Hyaluronic acid acts as a viscosupplement, restoring the viscoelastic properties of synovial fluid to provide lubrication and shock absorption. Triamcinolone hexacetonide is a potent anti-inflammatory corticosteroid that provides rapid pain relief. The University of Sao Paulo General Hospital conducted a Phase 4 study (NCT01813565) to determine the optimal dosing regimen (single vs. multiple injections) for this combination, aiming to improve clinical outcomes as measured by VAS, WOMAC, and Lequesne scores.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyaluronic acid + triamcinolone hexacetonide.